Lilly's Obesity Medicines Gaining Wider Insurance Coverage in the U.S.
Eli Lilly announced that its obesity medicines, Foundayo and Zepbound, will be covered by all three major pharmacy benefit managers (PBMs) starting June 1. This expansion allows millions of Americans to access these FDA-approved treatments through their existing insurance plans at low out-of-pocket costs as low as $25 per month for eligible patients.
Tickers: $LLY
Topics: GLP-1 medications insurance coverage obesity treatment